Literature DB >> 22267599

Effect of azithromycin on acid reflux, hiatus hernia and proximal acid pocket in the postprandial period.

W O Rohof1, R J Bennink, A A de Ruigh, D P Hirsch, A H Zwinderman, G E Boeckxstaens.   

Abstract

BACKGROUND: The risk for acidic reflux is mainly determined by the position of the gastric acid pocket. It was hypothesised that compounds affecting proximal stomach tone might reduce gastro-oesophageal reflux by changing the acid pocket position.
OBJECTIVE: To study the effect of azithromycin (Azi) on acid pocket position and acid exposure in patients with gastro-oesophageal reflux disease (GORD).
METHODS: Nineteen patients with GORD were included, of whom seven had a large hiatal hernia (≥3 cm) (L-HH) and 12 had a small or no hiatal hernia (S-HH). Patients were randomised to Azi 250 mg/day or placebo during 3 days in a crossover manner. On each study day, reflux episodes were detected using concurrent high-resolution manometry and pH-impedance monitoring after a standardised meal. The acid pocket was visualised using scintigraphy, and its position was determined relative to the diaphragm.
RESULTS: Azi reduced the number of acid reflux events (placebo 8.0±2.2 vs Azi 5.6±1.8, p<0.01) and postprandial acid exposure (placebo 10.5±3.8% vs Azi 5.9±2.5%, p<0.05) in all patients without affecting the total number of reflux episodes. Acid reflux occurred mainly when the acid pocket was located above, or at the level of, the diaphragm, rather than below the diaphragm. Treatment with Azi reduced hiatal hernia size and resulted in a more distal position of the acid pocket compared with placebo (below the diaphragm 39% vs 29%, p=0.03). Azi reduced the rate of acid reflux episodes in patients with S-HH (38% to 17%) to a greater extent than in patients with L-HH (69% to 62%, p=0.04).
CONCLUSION: Azi reduces acid reflux episodes and oesophageal acid exposure. This effect was associated with a smaller hiatal hernia size and a more distal position of the acid pocket, further indicating the importance of the acid pocket in the pathogenesis of GORD. CLINICAL TRIAL REGISTRATION: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1970 NTR1970.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22267599     DOI: 10.1136/gutjnl-2011-300926

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  15 in total

Review 1.  Management of the patient with incomplete response to PPI therapy.

Authors:  Peter J Kahrilas; Guy Boeckxstaens; Andre J P M Smout
Journal:  Best Pract Res Clin Gastroenterol       Date:  2013-06       Impact factor: 3.043

Review 2.  Long-term macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Ganapathi Iyer Parameswaran; Sanjay Sethi
Journal:  CMAJ       Date:  2014-08-05       Impact factor: 8.262

3.  The Relationship Between the Acid Pocket and GERD.

Authors:  Guy Boeckxstaens
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-09

4.  Hepatocyte Transplantation.

Authors:  Ira J Fox
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

5.  Management of the Acid Pocket.

Authors:  Peter J Kahrilas
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-09

6.  Azithromycin and COPD Exacerbations in the Presence or Absence of Symptoms or Active Treatment for Gastroesophageal Reflux.

Authors:  Frederick L Ramos; Sarah M Lindberg; Jason S Krahnke; John Connett; Richard K Albert; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2014-09-25

7.  Pediatric Gastroesophageal Reflux Clinical Practice Guidelines: Joint Recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition.

Authors:  Rachel Rosen; Yvan Vandenplas; Maartje Singendonk; Michael Cabana; Carlo DiLorenzo; Frederic Gottrand; Sandeep Gupta; Miranda Langendam; Annamaria Staiano; Nikhil Thapar; Neelesh Tipnis; Merit Tabbers
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-03       Impact factor: 2.839

8.  The antibiotic azithromycin is a motilin receptor agonist in human stomach: comparison with erythromycin.

Authors:  John Broad; Gareth J Sanger
Journal:  Br J Pharmacol       Date:  2013-04       Impact factor: 8.739

Review 9.  Ineffective esophageal motility: Concepts, future directions, and conclusions from the Stanford 2018 symposium.

Authors:  C Prakash Gyawali; Daniel Sifrim; Dustin A Carlson; Mary Hawn; David A Katzka; John E Pandolfino; Roberto Penagini; Sabine Roman; Edoardo Savarino; Roger Tatum; Michel Vaezi; John O Clarke; George Triadafilopoulos
Journal:  Neurogastroenterol Motil       Date:  2019-04-11       Impact factor: 3.960

10.  Volume, distribution and acidity of gastric secretion on and off proton pump inhibitor treatment: a randomized double-blind controlled study in patients with gastro-esophageal reflux disease (GERD) and healthy subjects.

Authors:  Andreas Steingoetter; Matthias Sauter; Jelena Curcic; Dian Liu; Dieter Menne; Michael Fried; Mark Fox; Werner Schwizer
Journal:  BMC Gastroenterol       Date:  2015-09-02       Impact factor: 3.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.